{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T22:12:49Z","timestamp":1765750369314,"version":"3.48.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paediatric-onset Multiple Sclerosis (POMS) is a rare autoimmune disorder of the central nervous system, primarily affecting children and adolescents, characterized by recurrent episodes of neurological impairment. This study delineates the global disease burden and epidemiological characteristics of this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on POMS were obtained from the 2021 Global Burden of Disease (GBD) Study, including estimates from 1990 to 2021. We described the global burden of POMS using incidence, prevalence, DALYs (Disability-Adjusted Life Years), YLDs (Years Lived with Disability), and age-standardized rates. We utilized the Joinpoint Regression Program to analyze the epidemiological trends of POMS disease burden over the past three decades. The Nordpred model was employed to project the future disease burden of POMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, the global incidence number of POMS was 1,899 (95% CI: 1,096\u20132,868), with an ASIR of 0.09 (95% CI: 0.05\u20130.14). The global prevalence number of POMS was 5,276 (95% CI: 2,921\u20137,880), with an ASPR of 0.25\u201395% CI: 0.14\u22120.38). The global DALYs for POMS was 3,073 (95% CI: 2,216\u20134,142), with an age-standardized DALYs rate of 0.15 (95% CI: 0.10\u20130.20). The global YLDs for POMS was 1,489 (95% CI: 737\u20132,529), with an age-standardized YLDs rate of 0.07 (95% CI: 0.03\u20130.12). Using Joinpoint Regression, we found that during 1990\u20132021, the AAPC for global ASIR was 0.07 (95% CI: 0.06\u20130.07), for global ASPR was 0.05 (95% CI: 0.05\u20130.05), for global age-standardized DALYs rate was \u22120.31 (95% CI: \u22120.34 to \u22120.28), and for global age-standardized YLDs rate was 0.05 (95% CI: 0.05\u20130.05). According to the Norpred model, by 2046, the global incidence number of POMS is projected to be 1,760 with an ASIR of 0.14. The global prevalence number of POMS is projected to be 4,915 with an ASPR of 0.38. The global DALYs number of POMS is projected to be 2,694 with an age-standardized DALYs rate of 0.21. The global YLDs number of POMS is projected to be 1,387 with an age-standardized YLDs rate of 0.11.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>POMS is characterized by a relatively low disease burden; however, it has shown a persistent upward trend in recent years. It is necessary to increase focus on this disease and develop new therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1679340","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T22:10:18Z","timestamp":1765750218000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global burden and epidemiological trends of paediatric-onset multiple sclerosis: a cross-sectional analysis of the 2021 global burden of disease study"],"prefix":"10.3389","volume":"13","author":[{"given":"Ziliang","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manyun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1007\/s00415-024-12281-9","article-title":"Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"271","author":"Hua","year":"2024","journal-title":"J Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103449","DOI":"10.1016\/j.autrev.2023.103449","article-title":"Multiple sclerosis and pregnancy: pathogenesis, influencing factors, and treatment options","volume":"22","author":"Wang","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"crossref","first-page":"101054","DOI":"10.1016\/j.spen.2023.101054","article-title":"Pediatric multiple sclerosis","volume":"46","author":"Kornbluh","year":"2023","journal-title":"Semin Pediatr Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"104097","DOI":"10.1016\/j.msard.2022.104097","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in pediatric onset multiple sclerosis","volume":"68","author":"Solmaz","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/0883073820941751","article-title":"Pediatric inflammatory and autoimmune neurologic disorders at a tertiary medical center","volume":"35","author":"Curcio","year":"2020","journal-title":"J Child Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40263-021-00887-w","article-title":"Multiple sclerosis in children: differential diagnosis, prognosis, and disease-modifying treatment","volume":"36","author":"Jakimovski","year":"2022","journal-title":"CNS Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e16284","DOI":"10.1111\/ene.16284","article-title":"Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: a systematic review and meta-analysis","volume":"31","author":"Hagbohm","year":"2024","journal-title":"Eur J Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejpn.2025.04.001","article-title":"Pediatric-onset multiple sclerosis in Greece: a single-center study of the risk factors and a review of the literature","volume":"55","author":"Bechlivani","year":"2025","journal-title":"Eur J Paediatr Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard","year":"2016","journal-title":"Neurol Clin"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1474-4422(24)00256-4","article-title":"Differential diagnosis of suspected multiple sclerosis: global health considerations","volume":"23","author":"Correale","year":"2024","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/S0140-6736(24)00769-4","article-title":"Findings from the global burden of disease study 2021","volume":"403","author":"Murray","year":"2024","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/S2665-9913(23)00098-X","article-title":"Global, regional, and national burden of low back pain, 1990\u20132020, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.puhe.2019.04.016","article-title":"Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China","volume":"172","author":"Liu","year":"2019","journal-title":"Public Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2328521","DOI":"10.1080\/07853890.2024.2328521","article-title":"Global burden of liver cirrhosis 1990\u20132019 and 20 years forecast: results from the global burden of disease study 2019","volume":"56","author":"Wang","year":"2024","journal-title":"Ann Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1738","DOI":"10.1002\/hsr2.1738","article-title":"Gender differences in the burden of multiple sclerosis in China from 1990 to 2019 and its 25-year projection: an analysis of the global burden of diseases study","volume":"6","author":"Wang","year":"2023","journal-title":"Health Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103621","DOI":"10.1016\/j.autrev.2024.103621","article-title":"Global incidence trends of autoimmune diseases from 1990 to 2021 and projections to 2050: a systemic analysis of the global burden of disease study 2021","author":"Hao","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1212\/WNL.0000000000207481","article-title":"Global barriers to the diagnosis of multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, Third Edition","volume":"101","author":"Solomon","year":"2023","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41582-025-01141-3","article-title":"Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis","volume":"21","author":"Moccia","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1177\/13524585251351860","article-title":"2024 revision of the McDonald diagnostic criteria for MS: substantial and substantive changes","volume":"31","author":"Cohen","year":"2025","journal-title":"Mult Scler"},{"key":"B26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.mric.2023.11.002","article-title":"Multiple sclerosis part 1: essentials and the McDonald criteria","volume":"32","author":"Gill","year":"2024","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"B27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00415-025-13395-4","article-title":"Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis","volume":"272","author":"Habek","year":"2025","journal-title":"J Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/acn3.52291","article-title":"Pediatric, adult, and late onset multiple sclerosis: cognitive phenotypes and gray matter atrophy","volume":"12","author":"De Meo","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5603\/PJNNS.a2020.0069","article-title":"Pediatric multiple sclerosis\u2014current status of epidemiology, diagnosis and treatment","volume":"54","author":"Brola","year":"2020","journal-title":"Neurol Neurochir Pol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1177\/1352458519863781","article-title":"Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort","volume":"26","author":"Hacohen","year":"2020","journal-title":"Mult Scler"},{"key":"B31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00247-019-04582-3","article-title":"Pediatric multiple sclerosis: from clinical basis to imaging spectrum and differential diagnosis","volume":"50","author":"Padilha","year":"2020","journal-title":"Pediatr Radiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.1007\/s00415-024-12610-y","article-title":"Pediatric-onset multiple sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod","volume":"271","author":"Carotenuto","year":"2024","journal-title":"J Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/13524585231171047","article-title":"Pediatric multiple sclerosis: the 2022 ECTRIMS lecture","volume":"29","author":"Banwell","year":"2023","journal-title":"Mult Scler"},{"key":"B34","doi-asserted-by":"publisher","first-page":"104069","DOI":"10.1016\/j.lpm.2021.104069","article-title":"Pediatric onset multiple sclerosis: future challenge for early diagnosis and treatment","volume":"50","author":"de Chalus","year":"2021","journal-title":"Presse Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","article-title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","volume":"20","author":"Fadda","year":"2021","journal-title":"Lancet Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"105849","DOI":"10.1016\/j.msard.2024.105849","article-title":"Anti-CD20 therapies for pediatric-onset multiple sclerosis: a systematic review","volume":"91","author":"Etemadifar","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ana.26322","article-title":"Comparing natural history of early and late onset pediatric multiple sclerosis","volume":"91","author":"De Meo","year":"2022","journal-title":"Ann Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11910-024-01354-x","article-title":"Artificial intelligence and multiple sclerosis","volume":"24","author":"Amin","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"055004","DOI":"10.1088\/2057-1976\/ace261","article-title":"Introducing radiomics model to predict active plaque in multiple sclerosis patients using magnetic resonance images","volume":"9","author":"Khajetash","year":"2023","journal-title":"Biomed Phys Eng Express"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s00415-012-6790-1","article-title":"Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis","volume":"260","author":"Dobson","year":"2013","journal-title":"J Neurol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1679340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T22:10:19Z","timestamp":1765750219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1679340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":40,"alternative-id":["10.3389\/fped.2025.1679340"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1679340","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1679340"}}